Mexico - Delayed Quote MXN

Bionano Genomics, Inc. (BNGO.MX)

72.85
+2.91
+(4.16%)
At close: May 14 at 12:16:18 PM CST
Loading Chart for BNGO.MX
  • Previous Close 69.94
  • Open 0.00
  • Bid 70.00 x --
  • Ask 85.00 x --
  • Day's Range 77.50 - 77.50
  • 52 Week Range 58.00 - 1,080.00
  • Volume 1
  • Avg. Volume 17
  • Market Cap (intraday) 245.067M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -1,034.63
  • Earnings Date Aug 5, 2025 - Aug 11, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. The company offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. It also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic data from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, the company offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

www.bionano.com

98

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BNGO.MX

View More

Performance Overview: BNGO.MX

Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

BNGO.MX
80.42%
S&P 500 (^GSPC)
1.34%

1-Year Return

BNGO.MX
93.71%
S&P 500 (^GSPC)
10.16%

3-Year Return

BNGO.MX
99.61%
S&P 500 (^GSPC)
46.03%

5-Year Return

BNGO.MX
99.95%
S&P 500 (^GSPC)
96.34%

Compare To: BNGO.MX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BNGO.MX

View More

Valuation Measures

Annual
As of 5/23/2025
  • Market Cap

    241.87M

  • Enterprise Value

    245.43M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.24

  • Price/Book (mrq)

    0.28

  • Enterprise Value/Revenue

    0.45

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -294.05%

  • Return on Assets (ttm)

    -31.04%

  • Return on Equity (ttm)

    -127.82%

  • Revenue (ttm)

    28.46M

  • Net Income Avi to Common (ttm)

    -83.7M

  • Diluted EPS (ttm)

    -1,034.63

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    18.23M

  • Total Debt/Equity (mrq)

    38.21%

  • Levered Free Cash Flow (ttm)

    497k

Research Analysis: BNGO.MX

View More

Company Insights: BNGO.MX

Research Reports: BNGO.MX

View More

People Also Watch